AU2006310338A1 - Adminstration routes for priming/boosting with influenza vaccines - Google Patents

Adminstration routes for priming/boosting with influenza vaccines Download PDF

Info

Publication number
AU2006310338A1
AU2006310338A1 AU2006310338A AU2006310338A AU2006310338A1 AU 2006310338 A1 AU2006310338 A1 AU 2006310338A1 AU 2006310338 A AU2006310338 A AU 2006310338A AU 2006310338 A AU2006310338 A AU 2006310338A AU 2006310338 A1 AU2006310338 A1 AU 2006310338A1
Authority
AU
Australia
Prior art keywords
vaccine
mucosal
influenza
parenteral
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006310338A
Other languages
English (en)
Inventor
Derek O'hagan
Michael Vajdy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Novartis Vaccines and Diagnostics SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics SRL filed Critical Novartis Vaccines and Diagnostics SRL
Publication of AU2006310338A1 publication Critical patent/AU2006310338A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2006310338A 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines Abandoned AU2006310338A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73402605P 2005-11-04 2005-11-04
US60/734,026 2005-11-04
US83633206P 2006-08-07 2006-08-07
US60/836,332 2006-08-07
PCT/GB2006/004132 WO2007052057A2 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines

Publications (1)

Publication Number Publication Date
AU2006310338A1 true AU2006310338A1 (en) 2007-05-10

Family

ID=37862714

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006310338A Abandoned AU2006310338A1 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines

Country Status (7)

Country Link
US (1) US20100158943A1 (enExample)
EP (1) EP1945253A2 (enExample)
JP (1) JP2009514840A (enExample)
AU (1) AU2006310338A1 (enExample)
CA (1) CA2628379A1 (enExample)
NZ (1) NZ567980A (enExample)
WO (1) WO2007052057A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007258874B2 (en) * 2006-06-15 2013-11-14 Seqirus UK Limited Adjuvant-sparing multi-dose influenza vaccination regimen

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
WO2009071633A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
WO2009156852A1 (en) * 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2596017B1 (en) * 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
WO2012114323A1 (en) * 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
JP2016502995A (ja) * 2012-12-17 2016-02-01 ユーロシネ ヴァクシンズ アクチエボラーグ 鼻腔内予防接種投薬レジメン
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US5643574A (en) * 1993-10-04 1997-07-01 Albany Medical College Protein- or peptide-cochleate vaccines and methods of immunizing using the same
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
JP2003509473A (ja) * 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US20040213745A1 (en) * 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007258874B2 (en) * 2006-06-15 2013-11-14 Seqirus UK Limited Adjuvant-sparing multi-dose influenza vaccination regimen

Also Published As

Publication number Publication date
US20100158943A1 (en) 2010-06-24
WO2007052057A2 (en) 2007-05-10
NZ567980A (en) 2012-01-12
EP1945253A2 (en) 2008-07-23
JP2009514840A (ja) 2009-04-09
WO2007052057A3 (en) 2007-07-12
CA2628379A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
US9901630B2 (en) Adjuvant-sparing multi-dose influenza vaccination regimen
AU2008269439B2 (en) Low-additive influenza vaccines
CA2671629C (en) Vaccines including antigen from four strains of influenza virus
AU2008331238B2 (en) Vaccination with multiple clades of H5 influenza A virus
AU2007231027B2 (en) Storage of influenza vaccines without refrigeration
US20100158943A1 (en) Administration routes for priming/boosting with influenza vaccines
AU2006310336B2 (en) Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20090285854A1 (en) Frozen stockpiling of influenza vaccines
HK1143085B (en) Low-additive influenza vaccines
HK1174281A (en) Low-additive influenza vaccines
HK1162312A (en) Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted